Status:
COMPLETED
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Open-Angle
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. P...
Eligibility Criteria
Inclusion
- Primary open-angle glaucoma in one eye
- Visual acuity 20/80 or better
- Intraocular pressure in the study eye ≤ 24 mm Hg
- Glaucomatous visual field loss - 7 dB to - 25 dB
Exclusion
- Known allergy to brimonidine tartrate
- Uncontrolled systemic disease or infection of the eye
- Recent eye surgery or injections in the eye
- Female patients who are pregnant, nursing or planning a pregnancy
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00693485
Start Date
September 1 2008
End Date
August 1 2011
Last Update
April 24 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Artesia, California, United States
2
Tel Aviv, Israel